PMID: 9448881Aug 1, 1997Paper

Low-risk febrile neutropenia in a medical oncology unit

Australian and New Zealand Journal of Medicine
D C LeongJ F Stewart

Abstract

Febrile neutropenia occurring in patients receiving chemotherapy for solid tumours or lymphoma is usually of short duration, and therefore may have a better outcome compared to patients with acute leukaemia or patients receiving myeloablative chemotherapy. To review retrospectively the outcomes for febrile neutropenia occurring in patients of the Medical Oncology Unit at our institution, and to identify factors associated with worse outcome, particularly prolonged admission or death. We reviewed 102 episodes of febrile neutropenia occurring in 85 patients treated between 1992 and 1994. Demographic factors, tumour-related factors and clinical aspects of the episodes were correlated with outcome. The median age was 60 years (range, 18-87), with 56 (55%) episodes occurring in females. Twenty-eight (27%) episodes occurred in patients with lymphoma, with the remaining 74 (73%) occurring in patients with solid tumours. At presentation, the median absolute neutrophil count (ANC) was 0.14 x 10(9)/L with a median duration of significant neutropenia (ANC < 0.5 x 10(9)/L) of three days. The median duration of fever was two days. Twenty-nine (28%) episodes had positive cultures; of these 11 had bacteraemia. Forty-four (43%) episodes were c...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A TalcottL Goldman
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A G FreifeldR C Young
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A TalcottR Finberg
Jun 1, 1996·Infectious Disease Clinics of North America·K V RolstonA Freifeld

❮ Previous
Next ❯

Citations

Mar 24, 2007·Clinical Cornerstone·Lee S Schwartzberg
Jun 22, 2005·The Oncologist·Gary H LymanOlayemi Agboola
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Emmanouil SaloustrosVassilis Georgoulias
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J KlaassenJ J Doyle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.